Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3041% below fair value
$1.00−0.02 (-1.96%)
Close on Nov 12, 2026Market cap $58.23MP/E –Yield –
Spero Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Spero Therapeutics's ebitda for the twelve months ending Dec 31, 2025 was $6.31M. For fiscal 2025 it was $6.31M. The highest annual figure on record is $21.85M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.31M | – |
| FY2024 | Dec 31, 2024 | -$73.36M | -435.8% |
| FY2023 | Dec 31, 2023 | $21.85M | – |
| FY2022 | Dec 31, 2022 | -$41.33M | – |
| FY2021 | Dec 31, 2021 | -$87.33M | – |
| FY2020 | Dec 31, 2020 | -$78.35M | – |
| FY2019 | Dec 31, 2019 | -$62.47M | – |
| FY2018 | Dec 31, 2018 | -$42.40M | – |
| FY2017 | Dec 31, 2017 | -$41.37M | – |
| FY2016 | Dec 31, 2016 | -$32.94M | – |
| FY2015 | Dec 31, 2015 | -$13.32M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $31.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.92M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.73M | -143.0% |
| Q3 FY2024 | Sep 30, 2024 | -$18.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.98M | – |
| Q4 FY2023 | Dec 31, 2023 | $50.57M | +94.1% |
| Q3 FY2023 | Sep 30, 2023 | -$1.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.11M | – |
| Q4 FY2022 | Dec 31, 2022 | $26.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$30.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.31M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.38M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.24M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.61M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.83M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.29M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.63M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.99M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.46M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.95M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.85M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.88M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.72M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.90M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.87M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.08M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.51M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.73M | – |
See a number that looks wrong?